Metis Global Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$44.3M Sell
48,212
-1,692
-3% -$1.72M 1.09% 15
2025
Q4
$53.6M Sell
49,904
-2,182
-4% -$2.09M 1.27% 13
2025
Q3
$39.7M Sell
52,086
-2,315
-4% -$1.72M 0.94% 14
2025
Q2
$42.4M Buy
54,401
+1,053
+2% +$818K 1.09% 14
2025
Q1
$44.1M Buy
53,348
+5,225
+11% +$4.35M 1.24% 13
2024
Q4
$37.2M Buy
48,123
+913
+2% +$756K 1.12% 13
2024
Q3
$41.8M Buy
47,210
+1,108
+2% +$996K 1.3% 12
2024
Q2
$41.7M Sell
46,102
-222
-0.5% -$178K 1.43% 12
2024
Q1
$36M Buy
46,324
+107
+0.2% +$76.1K 1.31% 12
2023
Q4
$26.9M Buy
46,217
+5,332
+13% +$3.11M 1.07% 16
2023
Q3
$22M Buy
40,885
+5,544
+16% +$2.86M 1.06% 15
2023
Q2
$16.6M Buy
35,341
+1,606
+5% +$674K 0.89% 16
2023
Q1
$11.6M Buy
33,735
+8,383
+33% +$2.83M 0.74% 20
2022
Q4
$9.27M Buy
25,352
+10,076
+66% +$3.57M 0.83% 19
2022
Q3
$4.94M Buy
15,276
+1,636
+12% +$518K 0.8% 17
2022
Q2
$4.42M Buy
13,640
+815
+6% +$245K 0.71% 23
2022
Q1
$3.67M Buy
12,825
+5,299
+70% +$1.36M 0.44% 31
2021
Q4
$2.08M Buy
+7,526
New +$1.91M 0.58% 32

Other funds holding LLY

Metis Global Partners's LLY Position: Q1 2026 in Review

Metis Global Partners reduced its Eli Lilly (LLY) stake by 3.4% in Q1 2026, selling an estimated $1.72M and leaving 48,212 shares worth $44.3M. The position accounts for 1.09% of the portfolio, ranked #15.

Metis Global Partners first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $53.6M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Metis Global Partners held 48,212 shares of Eli Lilly worth $44.3M as of Q1 2026.
  • Metis Global Partners sold 1,692 Eli Lilly shares in Q1 2026, an estimated $1.72M.
  • Eli Lilly made up 1.09% of Metis Global Partners's portfolio in Q1 2026, its #15 holding.
  • Metis Global Partners first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • Metis Global Partners's Eli Lilly position peaked at $53.6M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Metis Global Partners's 13F filing for Q1 2026, filed 7 May 2026.